These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 19578748

  • 1. MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.
    Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S, Haura EB.
    Int J Oncol; 2009 Aug; 35(2):337-45. PubMed ID: 19578748
    [Abstract] [Full Text] [Related]

  • 2. Physalin A exerts anti-tumor activity in non-small cell lung cancer cell lines by suppressing JAK/STAT3 signaling.
    Zhu F, Dai C, Fu Y, Loo JF, Xia D, Gao SP, Ma Z, Chen Z.
    Oncotarget; 2016 Feb 23; 7(8):9462-76. PubMed ID: 26843613
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.
    J Thorac Oncol; 2014 Apr 23; 9(4):488-96. PubMed ID: 24736071
    [Abstract] [Full Text] [Related]

  • 5. Overexpression of MUC1 enhances proangiogenic activity of non-small-cell lung cancer cells through activation of Akt and extracellular signal-regulated kinase pathways.
    Yao M, Zhang W, Zhang Q, Xing L, Xu A, Liu Q, Cui B.
    Lung; 2011 Dec 23; 189(6):453-60. PubMed ID: 21959954
    [Abstract] [Full Text] [Related]

  • 6. A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance.
    Zheng Q, Dong H, Mo J, Zhang Y, Huang J, Ouyang S, Shi S, Zhu K, Qu X, Hu W, Liu P, Wang Y, Zhang X.
    Theranostics; 2021 Dec 23; 11(2):824-840. PubMed ID: 33391507
    [Abstract] [Full Text] [Related]

  • 7. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.
    Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D.
    Mol Cancer Ther; 2011 May 23; 10(5):806-16. PubMed ID: 21421804
    [Abstract] [Full Text] [Related]

  • 8. Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer.
    Lin SY, Chang HH, Lai YH, Lin CH, Chen MH, Chang GC, Tsai MF, Chen JJ.
    PLoS One; 2015 May 23; 10(5):e0123305. PubMed ID: 25955608
    [Abstract] [Full Text] [Related]

  • 9. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC, Yeh HH, Huang WL, Yan JJ, Lai WW, Su WP, Chen HH, Su WC.
    Am J Respir Cell Mol Biol; 2013 Aug 23; 49(2):241-50. PubMed ID: 23526220
    [Abstract] [Full Text] [Related]

  • 10. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B, Ding CM, Li YX, Peng JC, Geng N, Qin WW.
    Oncol Rep; 2018 Mar 23; 39(3):1227-1234. PubMed ID: 29344640
    [Abstract] [Full Text] [Related]

  • 11. C-terminal tensin-like protein mediates invasion of human lung cancer cells and is regulated by signal transducer and activator of transcription 3.
    Bennett DT, Reece TB, Foley LS, Sjoberg A, Meng X, Fullerton DA, Weyant MJ.
    J Thorac Cardiovasc Surg; 2015 Jan 23; 149(1):369-75. PubMed ID: 25439778
    [Abstract] [Full Text] [Related]

  • 12. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM, Ge F, Chen XJ, Tang C, Ma J.
    Eur Rev Med Pharmacol Sci; 2019 Jun 23; 23(12):5242-5250. PubMed ID: 31298375
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB, Zheng Z, Song L, Cantor A, Bepler G.
    Clin Cancer Res; 2005 Dec 01; 11(23):8288-94. PubMed ID: 16322287
    [Abstract] [Full Text] [Related]

  • 15. Major vault protein suppresses lung cancer cell proliferation by inhibiting STAT3 signaling pathway.
    Bai H, Wang C, Qi Y, Xu J, Li N, Chen L, Jiang B, Zhu X, Zhang H, Li X, Yang Q, Ma J, Xu Y, Ben J, Chen Q.
    BMC Cancer; 2019 May 15; 19(1):454. PubMed ID: 31092229
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides.
    Weerasinghe P, Garcia GE, Zhu Q, Yuan P, Feng L, Mao L, Jing N.
    Int J Oncol; 2007 Jul 15; 31(1):129-36. PubMed ID: 17549413
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D.
    Cancer Res; 2016 Mar 15; 76(6):1538-48. PubMed ID: 26833129
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
    Jin H, Jiang AY, Wang H, Cao Y, Wu Y, Jiang XF.
    Mol Med Rep; 2017 Sep 15; 16(3):3475-3481. PubMed ID: 28713965
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.